在LI-RADS M类中,Gd-BOPTA增强MRI辅助影像特征对鉴别肝细胞癌与肝内肿块型胆管癌的附加价值
本回顾性研究纳入116个LI-RADS M类肝脏病灶(82例肝细胞癌、34例肝内肿块型胆管癌),在Gd-BOPTA增强MRI上比较主要征象与辅助影像特征对肝细胞癌诊断的价值,发现强化「包膜」是可靠征象,加入辅助特征后模型2的AUC显著优于模型1(0.918 vs 0.845,p=0.021),满足模型2中任意两个及以上预测因子时敏感度为91.46%、准确率最高为87.93%。
要点
- LI-RADS M类病灶中,强化「包膜」是鉴别肝细胞癌与肝内肿块型胆管癌的可靠影像征象。
- 加入辅助影像特征后模型2的AUC为0.918,显著优于模型1的0.845(p=0.021)。
- 满足模型2中任意两个及以上预测因子时,诊断肝细胞癌的敏感度为91.46%、准确率为87.93%。
核心结论
- 强化「包膜」是帮助识别肝细胞癌的可靠影像特征,加入辅助影像特征可提高LI-RADS M类中肝细胞癌与肝内肿块型胆管癌鉴别的敏感度和准确率。
研究设计与样本
- 回顾性研究,纳入116个经组织学证实的LI-RADS M类肝脏病灶(82个肝细胞癌、34个肝内肿块型胆管癌),在Gd-BOPTA增强MRI上构建并比较诊断模型1(基于LI-RADS主要征象、LR-M特征及临床病理因素)与模型2(加入辅助影像特征)。
关键影像表现/征象
- 82个肝细胞癌中49个(59.8%)出现强化「包膜」,频率显著高于肝内肿块型胆管癌(p<0.001)。
诊断标准与关键数值
- 模型1中,甲胎蛋白升高(OR=10.676,95%CI=2.125-4.470,p=0.004)和强化「包膜」(OR=20.558,95%CI=4.470-94.550,p<0.001)为独立危险因素。
- 模型2中,男性(OR=23.452,95%CI=1.465-375.404,p=0.026)、强化「包膜」(OR=13.161,95%CI=1.725-100.400,p=0.013)、分隔(OR=17.983,95%CI=1.049-308.181,p=0.046)、小范围中央肝胆期高信号(OR=44.386,95%CI=1.610-1223.484,p=0.025)为与肝细胞癌相关的独立显著变量。
- 模型2的AUC为0.918,显著优于模型1的0.845(p=0.021)。
- 满足模型2中任意两个及以上预测因子时,敏感度为91.46%,准确率最高为87.93%。
临床应用与阅片要点
- 在LI-RADS M类病灶中,可关注强化「包膜」以帮助鉴别肝细胞癌与肝内肿块型胆管癌。
- 结合辅助影像特征(分隔、小范围中央肝胆期高信号等)及临床病理因素可提高肝细胞癌诊断的敏感度和准确率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To identify the reliable imaging features and added-value of ancillary imaging features for differentiating hepatocellular carcinoma (HCC) and intrahepatic mass-forming cholangiocarcinoma (IMCC) assigned to LI-RADS M on Gd-BOPTA-enhanced MRI.
METHODS: This retrospective study included 116 liver observations assigned to LI-RADS M, including 82 HCC and 34 IMCC histologically confirmed. Before and after adding ancillary imaging features, all variables with a p-value of < 0.05 in univariable analysis were entered into a multivariable logistic regression analysis to build diagnostic model 1 and model 2 to find reliable predictors of HCC diagnosis. Receiver operating characteristic (ROC) analysis and the DeLong test were used to compare the two models.
RESULTS: Forty-nine of 82(59.8%) HCCs had a considerably higher frequency of enhancing "capsule" compared with IMCCs (p < 0.001). Based on LI-RADS major and LR-M features and clinical-pathologic factors, an elevated AFP level (OR = 10.676, 95%CI = 2.125-4.470, p = 0.004) and enhancing "capsule" (OR = 20.558, 95%CI = 4.470-94.550, p < 0.001) were extracted as independent risk factors in Model 1. After adding ancillary imaging features, Male (OR = 23.452, 95%CI = 1.465-375.404, p = 0.026), enhancing "capsule" (OR = 13.161, 95%CI = 1.725-100.400, p = 0.013), septum (OR = 17.983, 95%CI = 1.049-308.181, p = 0.046), small-scale central HBP hyperintensity (OR = 44.386, 95%CI = 1.610-1223.484, p = 0.025) were confirmed as independent significant variables associated with HCC. Model 2 demonstrated significantly superior AUC (0.918 vs 0.845, p = 0.021) compared with Model 1. When any two or more predictors in model 2 were satisfied, sensitivity was 91.46%, and accuracy was at the top (87.93%).
CONCLUSION: Enhancing "capsule" was a reliable imaging feature to help identify HCC. Adding ancillary imaging features improved sensitivity and accuracy for HCC diagnosis with differentiation from IMCC in LR-M.
引用
- Zheng, Huang, She, et al. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Abdom Radiol (NY). 2021. PMID: 34964069. doi:10.1007/s00261-021-03380-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。